Hematologic Malignancy
Blastic Plasmacytoid Dendritic Cell Neoplasm
CI-CAN-00001988BPDCNExplore in graph →
Hematologic16 active trials1 approved drugs
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001988BPDCNExplore in graph →
Clinical trials
41 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (8)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | terminated | Phase 2 | 150 | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03404193 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | terminated | Phase 2 | 235 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 10, 2026 |
| clinicaltrials |
| NCT04317781 | Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04109482 | Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. | terminated | Phase 1 / Phase 2 | 3 | Mustang BioINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT05645744 | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. | terminated | — | 3 | Mustang BioINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | terminated | Phase 2 | 12 | Mayo ClinicOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT03203369 | Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN(ABC123) | terminated | Phase 1 | 1 | Cellectis S.A.INDUSTRY | 1 | Jul 31, 2019 | clinicaltrials |
Data updated 22 days agoSource updated May 14, 2026source: clinicaltrials